Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

July 20, 2018
Alice Melãoby Alice Melão

In News.

Adding Imbruvica to R-CHOP Does Not Improve Outcomes for Newly Diagnosed DLBCL Patients, Phase 3 Trial Shows

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

Adding Imbruvica (ibrutinib) to a standard chemotherapy regimen does not improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma (NHL), a Phase 3 trial reports.

The trial — called DBL3001 (NCT01855750) — tested Imbruvica in patients with non-germinal center B cell (GCB) or activated B-cell (ABC) subtypes of the disease, which have limited responses to treatment.

While the combination was no better than R-CHOP chemotherapy at delaying disease progression, time to next therapy, or death — the study’s main measures — researchers did note improvements in a subpopulation of patients, warranting further analysis.

“Since its first U.S. FDA approval in 2013, Imbruvica has redefined standard of care in many different blood cancers — several of which had little to no treatment options available to patients before,” Thorsten Graef, MD, PhD, head of clinical development at Pharmacyclics, an AbbVie company, said in a press release. “We continue to believe that ibrutinib has great untapped potential as a cancer treatment alone or in combination.”

The trial included 838 patients with previously untreated GCB or ABC subtypes of DLBCL. Participants were randomly assigned Imbruvica plus R-CHOP chemotherapy or chemotherapy alone.

R-CHOP is the current standard of care for DLBCL patients. It is comprised of five agents — Rituxan (rituximab), cyclophosphamide, doxorubicin, vincristine, and prednisone.

The trial’s main goal was to extend event-free survival, deemed as the time a patient lives without disease worsening or without initiating of a subsequent lymphoma therapy.

But researchers also examined the time until disease progression or death, complete response rate, time to symptom worsening, and other measures of Imbruvica’s distribution and behavior in the body.

While the combination led to even-free survival at rates similar to the chemotherapy regimen alone, researchers reported clinically meaningful improvements in a patient subgroup and intent to analyze this finding further.  No further information was given.

“These medical achievements reflect our objective of focusing research where there is great unmet patient need and understanding that the nature of research is such that some studies succeed and others do not,” Graef said. “Together with our global partner Janssen, we are advancing our robust ibrutinib scientific development program and anticipate results from several studies in the future.”

AbbVie is planning to reveal the full results from the DBL3001 study at an upcoming scientific meeting.

Imbruvica is a Bruton’s tyrosine kinase inhibitor jointly developed and commercialized by Pharmacyclics and Janssen Biotech. It was first approved in the U.S. in 2013 and is currently used for the treatment of five B-cell blood cancers and chronic graft-versus-host-disease, for a total of eight indications.

Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged AbbVie, activated B cell-like DLBCL, DBL3001, ibrutinib, IMBRUVICA, Janssen Biotech, non-germinal center B-cell DLBCL, Non-Hodgkin Lymphoma, Pharmacyclics, Phase 3 trial.

Post navigation

rituximab biosimilars in EurpoePrevious: Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients
foodNext:How Cancer Made Me a More Conscious Consumer

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2022 Copyright 2015 © All rights reserved